Market research
RN3N.F Arena Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 95.25
- Dividend yield
- 0.0%
- Beta
- 0.55
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 95.25
- Dividend yield
- 0.0%
- Beta
- 0.55
About
About Arena Pharmaceuticals, Inc
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RN3N.F discussion.
5 years, 4 months ago
Arena Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 3.9% below its 200 day moving average.
From a valuation standpoint, the stock is 812.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11978.6.
Arena Pharmaceuticals, Inc's total revenue sank by 98.8% to $37K since the same quarter in the previous year.
Its net income has dropped by 38.3% to $-122M since the same quarter in the previous year.
Finally, its free cash flow fell by 68.2% to $-107M since the same quarter in the previous year.
Based on the above factors, Arena Pharmaceuticals, Inc gets an overall score of 0/5.